



All

Images

Videos

翻译成中文

关闭取词

7,070 Results

Any time ▾

HER2 aberrations and heterogeneity in cancers of the ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028807>

Sep 21, 2016 · Numerous preclinical and clinical studies, beginning with the intuition of Slamon and collaborators on the role of HER2 in breast **cancer**, have broadened our understanding of this oncogene in many human cancers, including digestive system cancers (DSC)[8,11]. While HER2 represents a prognostic marker of aggressive behavior in many DSC[8,12,13], the importance of this oncogene ...

Cited by: 10

Author: Nicola Fusco, Silvano Bosari

Publish Year: 2016

Targeted therapy for biliary tract cancers - Faris - 2012 ...

<https://onlinelibrary.wiley.com/doi/full/10.1007/s00534-011-0496-0>

The experience to date for ErbB2 inhibitors has been disappointing, with a phase II trial of **lapatinib**, a dual ErbB1/ErbB2 inhibitor, in the first- or second-line setting demonstrating no responses in 17 patients, comprised of 5 patients with **gallbladder** carcinoma, 3 with ampullary carcinoma, and ...

Cited by: 26

Author: Jason E. Faris, Andrew X. Zhu

Publish Year: 2012

ERBB2 and KRAS Alterations Mediate Response to EGFR ...

https://www.researchgate.net/publication/328207306_ERBB2_and_KRAS_Alterations_Mediate...

Nine patients with gallbladder cancer and five patients with cholangiocarcinoma had received **HER2/neu-directed therapy** (**trastuzumab**, **lapatinib**, or **pertuzumab**) during the study period.

Current biologics for treatment of biliary tract cancers ...

jgo.amegroups.com/article/view/13912/11520 ▾

Current biologics for treatment of biliary tract cancers Biliary tract cancers (BTC) is a group of malignancies that arise from the epithelial cells of the biliary tree. These cancers are typically classified by anatomic **site** of origin: intrahepatic cholangiocarcinoma (IHCC) and extrahepatic cholangiocarcinoma (EHCC), and **gallbladder cancer** (GBC).

Cited by: 5

Author: Diana Y. Zhao, Kian-Huat Lim

Publish Year: 2017

Targeted Therapy in Biliary Tract Cancers | SpringerLink

<https://link.springer.com/article/10.1007/s11864-015-0366-0> ▾

Aug 13, 2015 · **Biliary tract cancers** (BTC) are a heterogeneous group of **cancers** that are clinically and genetically divergent. BTC can be divided anatomically into **gallbladder cancers** (GBC), intrahepatic cholangiocarcinomas (IHCC), **hilar cholangiocarcinomas** (HCC), and **extrahepatic cholangiocarcinomas** (EHCC) [1].

Match Overview

1 Internet 46 words
crawled on 27-Jul-2018
pubs.acs.org

2%

2 Internet 12 words
crawled on 06-Jun-2017
ecancer.org

0K/s
0.1K/s
45%

1

2 INTRODUCTION

3 Gallbladder cancer (GBC) is an uncommon malignancy with an aggressive

4 clinical course. Its prevalence varies among geographical areas and is higher in

5 Asia and the Andes region^[1]. GBC constitutes bile duct cancer along with

6 intrahepatic cholangiocarcinoma (ICA) and extrahepatic cholangiocarcinoma

7 (ECA). However, these are distinct entities with significant differences in their

8 mutational landscape^[2]. For example, isocitrate dehydrogenase 1 or 2

9 mutations, breast cancer 1 associated protein-1 mutations, and fibroblast growth

10 factor receptors fusions are frequently seen in ICA, whereas Kirsten rat

VIP
0K/s
7.4K/s
45%



29,700 Results

Any time ▾

ERBB2 and KRAS alterations mediate response to EGFR ...

<https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.31916>

Additionally, consistent with a recent report that described alterations in ERBB2 and ERBB3 at a frequency of 9.8% and 11.8% respectively among Chinese gallbladder cancer, 19, 37 we found recurrent activating ERBB2 (V777L) mutation in 6 of 44 gallbladder cancer samples with an overall mutation frequency of 13%, in addition to IHC based over expression across 24% (6 of 25) primary tumors.

Cited by: 1

Author: Prajish Iyer, Shailesh V. Shrikhande, Mali...

Publish Year: 2018

Mutation Profiling in Cholangiocarcinoma: Prognostic and ...

<https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0115383> ▾

Dec 23, 2014 · ERBB2 GAs occurred in 6 cases, which included 2 amplifications and 4 somatic mutations. ERBB2 mutations have been described in non-small cell lung cancer, breast cancer, gastric cancer and colorectal cancer , . These mutations have ...

Cited by: 168

Author: Chaitanya R. Churi, Rachna Shroff, Ying ...

Publish Year: 2014

Current Management of Gallbladder Carcinoma - AlphaMed ...

theoncologist.alphamedpress.org/content/15/2/168.full

Feb 01, 2010 · Although anatomically these malignancies are related and have similar metastatic patterns, each has a distinct clinical presentation, molecular pathology, and prognosis. Gallbladder cancer (GBC) is the most common cancer of the biliary tract and has a particularly high incidence in Chile, Japan, and northern India.

Published in: [Oncologist](#) · 2010Authors: [Andrew X Zhu](#) · [Theodore S Hong](#) · [Aram F Hezel](#) · [David A Kooby](#)Affiliation: [Partners Healthcare](#)About: [Survival rate](#) · [Gallbladder Neoplasm](#) · [Combined Modality Therapy](#)

Assessment of ESR1 and ERBB2 mutations in estrogen ...

https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.1040

May 30, 2017 · Background: Mutations (mut) in ESR1 have been reported in ER+ breast cancers (BC) as an acquired resistance mut to aromatase inhibitor (AI) therapy. Acquired ERBB2 mut have also been reported in MBC patients (pts) that cause activated ERBB2 signaling. The emergence of acquired secondary mut presents challenges in effective treatment approaches.